Dataset Information
The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.
Ontology highlight
ABSTRACT: Background
Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker.Methods
We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET scans were obtained postoperatively for RT planning. We used Cox proportional hazards models with OS and PFS as endpoints, to test the prognostic value of FET PET biological tumor volume (BTV).Results
Median follow-up time was 14 months, and median OS and PFS were 16.5 and 6.5 months, respectively. In the multivariate analysis, increasing BTV (HR = 1.17, P?ConclusionLarge BTV on FET PET is an independent prognostic factor of poor OS and PFS in glioblastoma patients. With the introduction of FET PET, we obtain a prognostic index that can help in glioblastoma treatment planning.
SUBMITTER: Poulsen SH
PROVIDER: S-EPMC5281673 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Publications
The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.
European journal of nuclear medicine and molecular imaging 20160823 3
<h4>Background</h4>Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-<sup>18</sup>F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker.<h4>Methods</h4>We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET sca ...[more]